TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the Company’s patent application titled “Feeding Tube with Electromagnetic Sensor and Camera,” Application No. 18/199,059. The allowed patent includes 18 claims covering a feeding tube design that combines ...

Core Insights - ENvue Medical has signed a distribution agreement with U-Deliver to expand access to its ENFit Syringes across non-acute care channels nationwide [1][2] - The partnership aims to enhance ENvue's presence in the non-acute enteral care market, focusing on providing reliable and safe solutions for feeding and medication delivery [2] Company Overview - ENvue Medical, Inc. specializes in intelligent, non-invasive solutions for enteral care in clinical and home care settings, headquartered in Tyler, Texas [4] - The company has a research and development presence in Tel-Aviv and Nesher, Israel, and operates two distinct technology platforms [4] Product Details - ENvue's ENFit Syringes are available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and do not require a prescription [2] - The syringes meet ISO 80369-3 global standards and can be reused for up to seven days or 20 uses, ensuring safe enteral delivery [2] Partner Overview - U-Deliver is a U.S.-based supplier focused on enteral feeding supplies for home and long-term care settings, serving non-acute care customers through online and distribution channels [3]

Core Insights - ENvue Medical, Inc. has appointed Marc Waldman as Vice President, Commercial to lead its U.S. commercialization strategy and expand its presence in 38 hospitals [1][2] - Waldman brings over 35 years of experience in the medical device industry, having previously increased revenue from approximately $39 million to $70 million during his tenure as North America Sales Director at Avanos Medical [2] - The company specializes in non-invasive solutions for enteral care, with a focus on advancing patient safety and clinical usability [3][4] Company Overview - ENvue Medical, Inc. is headquartered in Tyler, Texas, and focuses on intelligent, non-invasive solutions for enteral care across clinical and home care settings [3] - The company operates two distinct technology platforms, including the ENvue™ Navigation Platform, which assists in placing feeding tubes and is FDA 510(k) cleared for adult use [4] - ENvue Medical also develops acoustic-based therapeutic technologies aimed at treating pain and reducing bacterial colonization [4]

Core Insights - ENvue Medical, Inc. has launched a new line of over-the-counter ENFit Syringes aimed at enhancing enteral care in both clinical and home settings, addressing the need for reliable and high-quality solutions as care shifts beyond hospitals [1][2] Product Launch - The ENFit Syringes are designed for feeding and medication delivery, available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and will be sold without a prescription through online retailers like Amazon [2] - These syringes comply with ISO 80369-3 global standards and can be reused for up to seven days or 20 uses, promoting safe and consistent enteral delivery [2] Company Overview - ENvue Medical specializes in intelligent, non-invasive solutions for enteral care, with headquarters in Tyler, Texas, and R&D facilities in Tel-Aviv and Nesher, Israel [3] - The company focuses on two technology platforms: the ENvue Navigation Platform for minimally invasive feeding tube placement and acoustic-based therapeutic technologies like PainShield® and UroShield® [4]

Core Insights - ENvue Medical has launched a new development program integrating its NanoVibronix technology to enhance comfort for patients using indwelling nasogastric (NG) tubes [1][2][3] - The program aims to address the discomfort commonly associated with prolonged use of NG tubes, which are essential in hospital care but often lead to nasal and throat discomfort [2][3] Company Overview - ENvue Medical, Inc. specializes in intelligent, non-invasive solutions for enteral care, operating in both clinical and home care settings [5] - The company is headquartered in Tyler, Texas, with research and development facilities in Tel-Aviv and Nesher, Israel [5] - ENvue Medical focuses on two main technology platforms: the ENvue™ Navigation Platform for minimally invasive feeding tube placement and the integration of vibration-based comfort technology [5] Technology and Development - The newly launched program is based on peer-reviewed clinical research showing that surface acoustic wave micro-vibration technology can reduce friction at the tube-tissue interface during NG tube use [2] - The initiative is exploratory and does not represent a commercial product launch or regulatory clearance, but aims to improve patient comfort and support the company's long-term strategy for enteral care [3] - The program will assess technical feasibility, clinical pathways, and regulatory considerations for incorporating vibration-based technology into ENvue's enteral ecosystem [3]

Core Viewpoint - ENvue Medical, Inc. will ring the Nasdaq Opening Bell on January 14, 2026, marking a significant milestone for the company in the medical technology sector [1][3]. Company Overview - ENvue Medical, Inc. specializes in non-invasive therapeutic systems, including enteral access solutions and non-opioid pain management [1][4]. - The company is headquartered in Tyler, Texas, with research and development facilities in Tel-Aviv and Nesher, Israel [4]. Leadership and Ceremony Details - The ceremony will be led by Doron Besser, MD, the CEO of ENvue Medical, along with the leadership team, directors, employees, and key stakeholders [2][3]. - The event will take place at Nasdaq MarketSite in Times Square, New York, from 8:30 A.M. to 9:45 A.M. ET [3]. Technology Platforms - ENvue Medical operates two distinct technology platforms: the ENvue™ Navigation Platform and acoustic-based therapeutic technologies [4][5]. - The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for placing feeding tubes, which has received FDA 510(k) clearance for adult use [5]. - Acoustic-based technologies, such as PainShield® and UroShield®, utilize proprietary low-intensity surface acoustic wave technology for pain treatment and bacterial colonization reduction [5].

Core Insights - NanoVibronix, Inc. will change its corporate name to ENvue Medical, Inc. effective December 12, 2025, to align with its strategic focus on the ENvue® feeding-tube placement system [1] - The company's stock ticker will change to "FEED" on the same date, with no action required from current stockholders [2] Company Strategy - The company aims to scale hospital utilization, enhance its commercial presence, and develop a comprehensive enteral-feeding ecosystem around ENvue through both internal and external opportunities [2] - The rebranding signifies a new phase characterized by precision enteral access, technology-driven growth, and clinical excellence [2] Company Overview - NanoVibronix, Inc. specializes in non-invasive and minimally invasive medical technology solutions, with headquarters in Tyler, Texas, and R&D in Nesher, Israel [3] - The company focuses on advancing standards in non-invasive therapy and minimally invasive navigation, emphasizing patient safety, clinical usability, and technological innovation [3] Product Information - The ENvue Navigation Platform is a minimally invasive electromagnetic navigation system designed to assist clinicians in placing feeding tubes, providing real-time visualization during the procedure [5] - The platform is FDA 510(k) cleared for adult use and may expand to include pediatric and vascular access applications in the future [5]